Amsterdam, the Netherlands and Las Vegas, Nevada – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas, Nevada from September 11 – 14, 2017, applying advanced technologies and deep clinical insights to address peripheral vascular needs. With the addition of its recent acquisition, Spectranetics, Philips will for the first time highlight its expanded portfolio of interventional X-ray systems, advanced catheters for measurement and therapy, clinical informatics, and services, including its Philips Azurion image-guided therapy platform, intravascular ultrasound (IVUS), Phoenix atherectomy system, and Spectranetics’ Stellarex drug-coated balloon.
More than eight million people in the U.S. alone are affected by peripheral arterial disease (PAD) . Many people do not experience symptoms and are not aware of even having the disease. In addition to having limited blood flow to the leg, patients are at increased risk for heart attack or stroke. Fortunately, PAD can be accessed and addressed through innovative solutions using minimally invasive procedures like atherectomy and imaging technology that may offer more accurate and reliable treatment options that can reduce recovery time for patients.
“At VIVA 17, we will share our expanded Philips and Spectranetics image-guided therapy portfolio enabling clinicians to decide, guide, treat and confirm the appropriate peripheral vascular therapy for patients around the world,” said Christopher Barys, Image Guided Therapy Devices Business Leader for Philips. “Our innovative therapeutic solutions are focused on delivering improved clinical and economic value and enhanced care.”